Central Nervous System (CNS) Drug Development Strategy: What is the Role of External Investment in this High-Risk Disease Space?

SUMMARY In 2018, Pfizer announced its plan to stop R&D activity in the central nervous system disease space and to create a venture fund that will invest in biotech firms conducting innovative neuroscience research The strategy of investing in a therapeutic space exclusively via corporate capital is coming into greater…

Applying Technology in Pharma (ATP): Assessment of Investment Trends in Digital Health

SUMMARY VC investment in digital healthcare has been growing rapidly (+42% vs. 2017) as the potential of new technology to solve complex issues, ranging from providing healthcare services to managing chronic conditions, evolves Most of these VC-backed digital healthcare companies aim to provide technology-enhanced solutions for providers and patients with…

Do Cutting-Edge One-Time Treatments Need Equally Innovative Outcomes or Annuity Based Payment Models?

 Following years of hushed excitement and mounting anticipation in biotech circles, gene and cell therapies finally made the jump in 2017 from the safety of guarded clinical trial experimentation to broad availability to patients and their caregivers in the USA.  The USA’s FDA (Food and Drug Administration) approvals of the…

Page 1 of 8123...Last »